Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03449381
Title	This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Boehringer Ingelheim
Indications	glioblastoma sarcoma lung non-squamous non-small cell carcinoma Advanced Solid Tumor transitional cell carcinoma
Therapies	BI 907828
Age Groups:	adult \| senior
Covered Countries	USA \| ESP \| DEU \| CAN \| BEL